{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:13:49Z","timestamp":1789132429313,"version":"build-2803163510"},"reference-count":62,"publisher":"American Society of Consultant Pharmacists","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:p>Various comorbidities and extensive medication regimens often complicate the management of gout in older adults. Even in the general population, managing gout can be challenging, as clinicians must develop strategies for acute gout treatment, assess the need for chronic management,\n and optimize prophylaxis for gout flares. Several factors influence the choice of pharmacologic therapy, including the patient\u2019s medical history, current medications, social and family history, ethnicity, age, and care preferences. This article reviews gout management with a focus on\n older adults through a case study approach, highlighting the importance of shared decision-making. The integration of pharmacists into direct patient care introduces a novel model of pharmacist-led gout management, which can improve adherence to urate-lowering therapy and optimize medication\n selection. Despite the rising prevalence of gout, it remains one of the most poorly managed diseases. This review aims to emphasize key principles for effective and safe gout management, taking into account the comorbidities and medications commonly encountered in the older adult population.<\/jats:p>","DOI":"10.4140\/tcp.n.2025.379","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:30:27Z","timestamp":1759465827000},"page":"379-389","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on the Management of Hyperuricemia and Gout in Older Adults"],"prefix":"10.4140","volume":"40","author":[{"given":"Madison W.","family":"Carter","sequence":"first","affiliation":[{"name":"1Boise VA Medical Center, Boise, Idaho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef M.","family":"Roman","sequence":"additional","affiliation":[{"name":"1Boise VA Medical Center, Boise, Idaho"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American College of Rheumatology guideline for the management of gout.","volume":"72","year":"2020","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"ref2","first-page":"35","article-title":"Treatment options for acute gout.","volume":"33","year":"2016","journal-title":"Fed Pract."},{"issue":"10156","key":"ref3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.","volume":"392","year":"2018","journal-title":"Lancet."},{"issue":"3","key":"ref4","first-page":"15","article-title":"A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial.","volume":"20","year":"2016","journal-title":"Perm J."},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial.","volume":"132","year":"2019","journal-title":"Am J Med."},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.51866\/rv1165","article-title":"Management of gout in the primary care setting.","volume":"17","year":"2022","journal-title":"Malays Fam Physician."},{"key":"ref7","article-title":"Colchicine. In: StatPearls [Internet].","year":"2025","journal-title":"Treasure Island, FL: StatPearls Publishing;"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians.","volume":"166","year":"2017","journal-title":"Ann Intern Med."},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.","volume":"62","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1517\/14656566.2010.529432","article-title":"Colchicine for the treatment of gout.","volume":"11","year":"2010","journal-title":"Expert Opin Pharmacother."},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/futurepharmacol2020011","article-title":"Pharmacogenetic perspective for optimal gout management.","volume":"2","year":"2022","journal-title":"Future Pharmacology."},{"key":"ref12","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management.","year":"2022","journal-title":"NEJM Evid."},{"issue":"Database issue","key":"ref13","first-page":"D784","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.","volume":"43","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","article-title":"Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.","volume":"20","year":"2017","journal-title":"Int J Rheum Dis."},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.","volume":"46","year":"2007","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","article-title":"Up-titration of allopurinol in patients with gout.","volume":"44","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"ref17","article-title":"Allopurinol. In: StatPearls [Internet].","year":"2025","journal-title":"Treasure Island, FL: StatPearls Publishing;"},{"key":"ref18","article-title":"Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review.","year":"2025","journal-title":"J Nephrol."},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD.","volume":"70","year":"2017","journal-title":"Am J Kidney Dis."},{"issue":"13","key":"ref20","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout.","volume":"378","year":"2018","journal-title":"N Engl J Med."},{"issue":"10264","key":"ref21","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.","volume":"396","year":"2020","journal-title":"Lancet."},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"e0264627","DOI":"10.1371\/journal.pone.0264627","article-title":"Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.","volume":"17","year":"2022","journal-title":"PLoS One."},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"24598","DOI":"10.1038\/s41598-024-74154-5","article-title":"Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators.","volume":"14","year":"2024","journal-title":"Sci Rep."},{"issue":"2","key":"ref24","first-page":"209","article-title":"Management of gout: update from the American College of Rheumatology.","volume":"104","year":"2021","journal-title":"Am Fam Physician."},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.","volume":"77","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.","volume":"64","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/2040622312462056","article-title":"Latest evidence on gout management: what the clinician needs to know.","volume":"3","year":"2012","journal-title":"Ther Adv Chronic Dis."},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.","volume":"40","year":"2013","journal-title":"J Rheumatol."},{"key":"ref29","article-title":"Impact of adding urine alkalization therapy to xanthine oxidase inhibitor in gout management: a prospective cohort study.","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa668","article-title":"The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study.","volume":"60","year":"2021","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.","volume":"39","year":"2012","journal-title":"J Rheumatol."},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR).","volume":"48","year":"2021","journal-title":"J Rheumatol."},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","article-title":"Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase.","volume":"6","year":"2019","journal-title":"Rheumatol Ther."},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/2042098617727714","article-title":"Pegloticase in gout treatment\u2014safety issues, latest evidence and clinical considerations.","volume":"8","year":"2017","journal-title":"Ther Adv Drug Saf."},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.2014.97","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.","volume":"96","year":"2014","journal-title":"Clin Pharmacol Ther."},{"issue":"24","key":"ref36","article-title":"Preliminary investigation into the prevalence of G6PD deficiency in a pediatric African American population using a near-patient diagnostic platform.","volume":"13","year":"2023","journal-title":"Diagnostics (Basel)."},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","article-title":"Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review.","volume":"25","year":"2023","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14397595.2017.1318467","article-title":"Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting.","volume":"28","year":"2018","journal-title":"Mod Rheumatol."},{"issue":"10413","key":"ref39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(23)01689-6","article-title":"Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.","volume":"402","year":"2023","journal-title":"Lancet."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.01.004","article-title":"The impact of colchicine on patients with acute and chronic coronary artery disease.","volume":"125","year":"2024","journal-title":"Eur J Intern Med."},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/ATVBAHA.124.319851","article-title":"Colchicine\u2019s role in cardiovascular disease management.","volume":"44","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1244529","DOI":"10.3389\/fcvm.2023.1244529","article-title":"Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial.","volume":"10","year":"2023","journal-title":"Front Cardiovasc Med."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2022.12.026","article-title":"Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial.","volume":"372","year":"2023","journal-title":"Int J Cardiol."},{"issue":"9","key":"ref44","first-page":"859866","article-title":"Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome.","volume":"78","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"26","key":"ref45","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","year":"2019","journal-title":"N Engl J Med."},{"issue":"19","key":"ref46","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease.","volume":"383","year":"2020","journal-title":"N Engl J Med."},{"issue":"3","key":"ref47","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/ajcn\/nqac140","article-title":"Effects of vitamin C supplementation on gout risk: results from the Physicians\u2019 Health Study II trial.","volume":"116","year":"2022","journal-title":"Am J Clin Nutr."},{"issue":"6","key":"ref48","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.37925","article-title":"Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.","volume":"65","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout.","volume":"124","year":"2011","journal-title":"Am J Med."},{"issue":"8","key":"ref50","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","article-title":"The challenges of gout management in the elderly.","volume":"28","year":"2011","journal-title":"Drugs Aging."},{"issue":"25","key":"ref51","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy.","volume":"316","year":"1987","journal-title":"N Engl J Med."},{"issue":"3","key":"ref52","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management.","volume":"50","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","article-title":"Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management.","volume":"46","year":"2023","journal-title":"Drug Saf."},{"issue":"6","key":"ref54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.ajkd.2022.04.006","article-title":"Initiation dose of allopurinol and the risk of severe cutaneous reactions in older adults with CKD: a population-based cohort study.","volume":"80","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.140588","article-title":"Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.","volume":"42","year":"2015","journal-title":"J Rheumatol."},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jppr.1511","article-title":"Management of gout in older people.","volume":"49","year":"2019","journal-title":"J Pharm Pract Res."},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1055\/s-0042-113183","article-title":"Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study.","volume":"66","year":"2016","journal-title":"Drug Res (Stuttg)."},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.33315","article-title":"Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.","volume":"64","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref59","first-page":"1045561","article-title":"Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: a real-world analysis using the FDA adverse event reporting system.","volume":"13","year":"2022","journal-title":"Front Pharmacol."},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.1056","article-title":"Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.","volume":"20","year":"2018","journal-title":"Eur J Heart Fail."},{"issue":"14","key":"ref61","first-page":"e674","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"147","year":"2023","journal-title":"Circulation."},{"issue":"5","key":"ref62","first-page":"679","article-title":"Drug-induced hyperuricaemia and gout.","volume":"56","year":"2017","journal-title":"Rheumatology (Oxford)."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000010\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:31:31Z","timestamp":1759811491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"alternative-id":["2639-9636(20251001)40:10L.379;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.379","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}